We're very excited about the Otaba robotic platform. Listen, we've been late to the market. We were the gold standard in operating rooms for probably two, three decades, if not longer.And we were late to the game with robotics with Ethicon. Exactly. And surgical instruments are still kind of the gold standard within the operating room, but we didn't have the robot capabilities to go with it.We're very excited about a submission we made to the FDA late last year. We're hopeful for approval later this year. ...

Healthcare giant Johnson & Johnson reported nearly 10% revenue growth for the latest quarter on strong cancer drug sales that offset a steep decline from one of its best-selling drugs, Stelara https://t.co/XLsm0a9nZS ...

Johnson & Johnson reported first-quarter sales above Wall Street’s expectations and bumped up its outlook for the year https://t.co/qjdR7vsXBw ...

Earnings SZN is here 🔔This week, we’re getting Q1 2026 results from:• JPM: The biggest US bank by assets 🏦• JNJ & ABT: Two of heathcare’s top "Dividend Kings” 🏥• PEP: A consumer staples giant 🥤• TSM: The foundry making chips for Apple, Nvidia, and AMD 👾• NFLX: A key read on streaming economy health 📺 ...

Group 1 - Major banks are starting to report their first-quarter earnings, indicating a significant period for financial performance assessment [1] - Other companies set to report earnings include Abbott Laboratories, PepsiCo, and ASML, highlighting a diverse range of sectors [1] - Economic data releases will cover producer prices, housing, and small business sentiment, which are critical indicators of economic health [1]

Core Viewpoint - The article suggests that despite rising implied volatility and market uncertainty, investors should consider certain dividend stocks as stable investment options. Group 1: Johnson & Johnson - Johnson & Johnson has an AAA credit rating, which is higher than that of the U.S. government, making it a reliable choice for investors [3] - The current market capitalization of Johnson & Johnson is $589 billion, with a current stock price of $244.49 and a dividend yield of 2.13% [4][5] - The company has a history of increasing dividends for 63 consecutive years, positioning it as a member of the Dividend Kings [5] - Healthcare demand remains steady regardless of market conditions, suggesting that Johnson & Johnson's business will continue to perform well even in adverse economic situations [6] Group 2: PepsiCo - PepsiCo has diversified its portfolio beyond sodas, owning a wide range of food and drink brands, which enhances its market presence [7] - The current market capitalization of PepsiCo is $212 billion, with a stock price of $155.29 and a dividend yield of 3.66% [8][9] - The company has strong brand loyalty, providing it with pricing power, and it has increased its dividend for 54 consecutive years, also classifying it as a Dividend King [9] Group 3: Walmart - Walmart is highlighted as a recession-resistant stock due to its strong underlying business model and everyday low prices [10] - The current market capitalization of Walmart is $991 billion, with a stock price of $124.28 and a dividend yield of 0.77% [11][12] - Walmart has a history of increasing dividends for 53 consecutive years, making it another member of the Dividend Kings, despite its lower dividend yield [12]

Investment Thesis - Johnson & Johnson (NYSE: JNJ) is valued with a Hold judgment, recognized for being one of the largest and most diversified players in the pharmaceutical industry, and has a long history of dividend increases spanning 62 years [1] Valuation Analysis - A quantitative evaluation using a Monte Carlo DCF model indicates that the stock is overvalued in slightly more than 1 out of 2 possible future scenarios [2] Performance Comparison - In terms of risk-adjusted performance, Johnson & Johnson ranks second among its peers, with only Eli Lilly (LLY) performing better. A structural break was identified in the Fama-French regression analysis after mid-2024, and the rolling Jensen's alpha has shown recovery following litigation events [3] Dividend Performance - Johnson & Johnson has a payout ratio of 64%, one of the lowest in its peer group, indicating potential for dividend increases in the coming year. However, the current dividend return is insufficient to compensate for the risk taken by investors, highlighting the need for capital increases to address the 1.13% gap between equity return and cost of equity [4] Company Overview - Johnson & Johnson is one of the largest and most recognized companies in the pharmaceutical industry, with a diverse range of specializations including pharmaceuticals [5]

Core Viewpoint - Equity markets are experiencing significant volatility, making dividend stocks an attractive investment option due to their ability to provide consistent payouts and stability during economic challenges [1] Company Overview - Johnson & Johnson (NYSE: JNJ) is highlighted as a standout dividend company, being part of the "Dividend Kings" group, which consists of companies with 50 or more consecutive annual dividend increases [2] - The company has increased its dividends for 63 consecutive years, showcasing a strong track record among its peers [2] Business Operations - Johnson & Johnson's pharmaceutical division has a diverse portfolio, including drugs in major therapeutic areas like immunology and oncology, with several products generating over $1 billion in annual sales [3] - The company is well-positioned to recover from challenges such as patent expirations, as evidenced by its response to the introduction of biosimilars for Stelara [3] Financial Performance - Johnson & Johnson projects sales to reach $100 billion this year, marking only the second instance of a biopharma company achieving this milestone, despite facing government-led price negotiations that may lower sales for some products [4] - The company has a robust pipeline that is expected to yield additional successful products over time [4] Medical Device Segment - The medical device business of Johnson & Johnson is also diversified, with recent efforts to gain approval for the Ottava robotic-assisted surgery system, targeting a promising niche in robotic surgery [5] Financial Health - Johnson & Johnson holds a AAA rating from S&P Global, indicating the highest level of financial health and stability [5]

Core Viewpoint - Johnson & Johnson stock is experiencing a rebound after a period of sideways trading, with a notable 43% increase over the past year, and is currently forming a flat base with a buy point of $251.71 [2][4]. Company Performance - Johnson & Johnson's innovative medicines division is projected to contribute 64% of total sales in the first quarter [4]. - The company is set to report its first-quarter earnings on April 14, with analysts expecting adjusted earnings of $2.68 per share on sales of $23.61 billion, indicating a sales growth of nearly 8% despite a projected earnings dip of over 3% [8][9]. Product Developments - Recent studies show that nearly 60% of adolescents with plaque psoriasis achieved clear skin after a year of treatment with the drug Icotyde, with 86% of patients experiencing a 90% reduction in psoriatic lesions [5]. - Johnson & Johnson reported that 89% of patients responded positively to an experimental treatment for bladder cancer and has submitted an application for European approval of Tecvayli for advanced multiple myeloma [6]. - The European Commission approved the prostate cancer pill Akeega, and the FDA granted Fast Track designation to nipocalimab for lupus patients [7]. Market Position - Johnson & Johnson stock has an IBD Composite Rating of 91, indicating it outperforms 91% of all stocks based on fundamental and technical measures [11]. - The stock's relative strength rating is also higher than the broader medical-diversified industry group, which has an RS Rating of 68 [12]. Sales Projections - The company's leading product, Darzalex, is expected to generate $3.85 billion in sales, growing nearly 19%, while Tremfya sales are projected to surge over 49% to $1.43 billion [9][10]. - Medical device sales are anticipated to increase by 6.5% to $8.54 billion [10].

Group 1 - Ariel Focus Fund reported a decline of -0.50% in Q4 2025, underperforming the S&P 500 and Russell 1000 Value indices, which gained +2.66% and +3.81% respectively, but achieved a +20.97% return over the full year [1] - The U.S. market environment in Q4 2025 was characterized by easing inflation, stable corporate earnings, and optimism around accommodative monetary policy, alongside strength in AI and cloud-driven technology stocks [1] - The fund maintained a disciplined, long-term investment approach, selectively adding to positions without making exits during the quarter [1] Group 2 - Johnson & Johnson (NYSE: JNJ) experienced a one-month return of -1.73%, with shares trading between $141.50 and $251.71 over the last 52 weeks, closing at approximately $242.49 on March 30, 2026, with a market capitalization of about $584.38 billion [2] - Johnson & Johnson's performance was bolstered by strong earnings and an increase in full-year revenue guidance, focusing on six priority areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision [3] - The company is entering a new era of accelerated growth and innovation, supported by key growth products and a robust pipeline, reaffirming confidence in its long-term prospects [3]